Loading clinical trials...
Loading clinical trials...
A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)
Conditions
Interventions
Atezolizumab
Sacituzumab govitecan
Locations
7
United States
University of California San Francisco
San Francisco, California, United States
University of Chicago Medical Center
Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
New Lenox, Illinois, United States
University of Chicago Medical Center for Advanced Care Orland Park
Orland Park, Illinois, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of Pennsylvania-Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Start Date
July 2, 2020
Primary Completion Date
December 30, 2026
Completion Date
December 30, 2027
Last Updated
August 19, 2025
NCT07040891
NCT07547774
NCT06257264
NCT07525869
NCT07347600
NCT04740697
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions